ALACHUA, FL - Oragenics Inc. (ONI BioPharma Inc.) (AMEX: ONI) has entered into a definitive financing agreement providing for equity financing of $2,600,000 consisting of common stock at 45 cents per share and warrants with an exercise price of $1.30 per share.

Stanley B. Stein, the company’s president and CEO, said, “This capital will help the company to begin generating revenue from our Probiora3 oral health product, to accelerate our efforts to develop and commercialize our proprietary DPOLT antibiotic platform, to test our SMaRT Replacement Therapy product for the elimination of tooth decay, to market our LPT3-04 weight loss product, and continue the development of our unique diagnostic platforms, IVIAT and CMAT, as well as other uses.”
http://www.techjournalsouth.com/news/article.html?item_id=5462